Novolog Pharm Financials
| NVLG Stock | 169.90 0.50 0.30% |
Novolog |
Please note, the presentation of Novolog Pharm's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novolog Pharm's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Novolog Pharm's management manipulating its earnings.
Novolog Pharm Stock Summary
Novolog Pharm competes with Bezeq Israeli, Nova, Enlight Renewable, Tadiran Hldg, and Azrieli. Novolog Ltd operates as a health logistics company in Israel. Novolog Ltd operates as a subsidiary of Pharm-Up Ltd. Novolog Ltd operates under Medical Care classification in Israel and is traded on Tel Aviv Stock Exchange.| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| ISIN | IL0011401515 |
| Business Address | 55 HaMaayan Street, |
| Sector | Health Care Providers & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.novolog.co.il |
| Phone | 972 8 660 4400 |
You should never invest in Novolog Pharm without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Novolog Stock, because this is throwing your money away. Analyzing the key information contained in Novolog Pharm's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Novolog Pharm Key Financial Ratios
Novolog Pharm's financial ratios allow both analysts and investors to convert raw data from Novolog Pharm's financial statements into concise, actionable information that can be used to evaluate the performance of Novolog Pharm over time and compare it to other companies across industries.Novolog Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novolog Pharm's current stock value. Our valuation model uses many indicators to compare Novolog Pharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novolog Pharm competition to find correlations between indicators driving Novolog Pharm's intrinsic value. More Info.Novolog Pharm Up 1966 is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.16 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novolog Pharm Up 1966 is roughly 6.09 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novolog Pharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novolog Pharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Novolog Pharm Up Systematic Risk
Novolog Pharm's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novolog Pharm volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Novolog Pharm Up correlated with the market. If Beta is less than 0 Novolog Pharm generally moves in the opposite direction as compared to the market. If Novolog Pharm Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novolog Pharm Up is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novolog Pharm is generally in the same direction as the market. If Beta > 1 Novolog Pharm moves generally in the same direction as, but more than the movement of the benchmark.
Novolog Pharm December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Novolog Pharm help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novolog Pharm Up 1966. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novolog Pharm Up 1966 based on widely used predictive technical indicators. In general, we focus on analyzing Novolog Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novolog Pharm's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.49 | |||
| Information Ratio | 0.1206 | |||
| Maximum Drawdown | 11.46 | |||
| Value At Risk | (2.20) | |||
| Potential Upside | 4.31 |
Complementary Tools for Novolog Stock analysis
When running Novolog Pharm's price analysis, check to measure Novolog Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novolog Pharm is operating at the current time. Most of Novolog Pharm's value examination focuses on studying past and present price action to predict the probability of Novolog Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novolog Pharm's price. Additionally, you may evaluate how the addition of Novolog Pharm to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |